OBJECTIVES: The purpose of this study was to assess the impact of acute myeloid leukemia (AML) and its treatment on health-related quality of life (HRQOL) by comparing the HRQOL of AML survivors with the HRQOL in the general population. METHODS: Two HRQOL questionnaires (EQ-5D and QLQ-C30) were sent to patients diagnosed with AML between 1999 and 2011 at a single academic hospital and still alive in 2012. HRQOL in AML survivors was compared with general population reference values. Multivariate analysis was used to identify factors associated with HRQOL in AML survivors. RESULTS: Questionnaires were returned by 92 of the 103 patients (89%). AML survivors reported significantly worse functioning, more fatigue, pain, dyspnea, appetite loss, and financial difficulties and lower EQ-VAS scores than the general population (P < 0.05). Impaired HRQOL in AML survivors was mainly found in survivors without a paid job. Other factors associated with a poor HRQOL were allogeneic hematopoietic stem cell transplantation and the absence of social support. CONCLUSION: This single-center study showed that the HRQOL in AML survivors is worse than the HRQOL in the general population. HRQOL in these patients can be improved by adequately treating and preventing fatigue, pain, dyspnea, and appetite loss.
OBJECTIVES: The purpose of this study was to assess the impact of acute myeloid leukemia (AML) and its treatment on health-related quality of life (HRQOL) by comparing the HRQOL of AML survivors with the HRQOL in the general population. METHODS: Two HRQOL questionnaires (EQ-5D and QLQ-C30) were sent to patients diagnosed with AML between 1999 and 2011 at a single academic hospital and still alive in 2012. HRQOL in AML survivors was compared with general population reference values. Multivariate analysis was used to identify factors associated with HRQOL in AML survivors. RESULTS: Questionnaires were returned by 92 of the 103 patients (89%). AML survivors reported significantly worse functioning, more fatigue, pain, dyspnea, appetite loss, and financial difficulties and lower EQ-VAS scores than the general population (P < 0.05). Impaired HRQOL in AML survivors was mainly found in survivors without a paid job. Other factors associated with a poor HRQOL were allogeneic hematopoietic stem cell transplantation and the absence of social support. CONCLUSION: This single-center study showed that the HRQOL in AML survivors is worse than the HRQOL in the general population. HRQOL in these patients can be improved by adequately treating and preventing fatigue, pain, dyspnea, and appetite loss.
Authors: Kuang-Hsi Chang; Wen-Li Hwang; Chih-Hsin Muo; Chung Y Hsu; Chieh-Lin Jerry Teng Journal: Support Care Cancer Date: 2016-08-09 Impact factor: 3.603
Authors: Gabriel Tremblay; Clemence Cariou; Christian Recher; Mike Dolph; Patricia Brandt; Anne-Sandrine Blanc; Anna Forsythe Journal: Eur J Health Econ Date: 2020-01-22
Authors: A Im; S A Mitchell; S M Steinberg; L Curtis; A Berger; K Baird; Z Kuzmina; G Joe; L E Comis; M Juckett; D Avila; J Baruffaldi; L Masuch; F Pirsl; S Z Pavletic Journal: Bone Marrow Transplant Date: 2016-02-01 Impact factor: 5.483
Authors: Øystein Bruserud; Galina Tsykunova; Maria Hernandez-Valladares; Hakon Reikvam; Tor Henrik Anderson Tvedt Journal: Pharmaceuticals (Basel) Date: 2021-05-02
Authors: Anna Forsythe; Patricia S Brandt; Mike Dolph; Sachin Patel; Adrian Paul J Rabe; Gabriel Tremblay Journal: Clinicoecon Outcomes Res Date: 2018-01-25